X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
XPro (XPro1595, pegipanermin) is a next-generation selective TNF inhibitor that is currently in clinical trials. It acts differently than currently available TNF inhibitors by neutralizing soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors.
Lead Product(s): Pegipanermin
Therapeutic Area: Neurology Product Name: XPro1595
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
XPro (pegipanermin) is a dominant-negative inhibitor of soluble TNF. It is being evaluated in phase 2 clinical trials for the treatment of Alzheimer’s Disease.
Lead Product(s): Pegipanermin
Therapeutic Area: Neurology Product Name: XPro
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2024
Details:
INKmune is an NK cell targeted therapy that is not an NK cell. INKmune™ designed to improve the function of the patient’s own NK cells. It is under phase 1/2 clinical development for the treatment of patients with Metastatic Castration-Resistant Prostate Cancer.
Lead Product(s): INKmune
Therapeutic Area: Oncology Product Name: INKmune
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
XPro (XPro1595, pegipanermin) is a next-generation selective TNF inhibitor that is currently in clinical trials. It acts differently than currently available TNF inhibitors by neutralizing soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors.
Lead Product(s): Pegipanermin
Therapeutic Area: Neurology Product Name: XPro1595
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
XPro™ (XPro1595, pegipanermin) is a next-generation selective TNF inhibitor that is currently in clinical trials. It acts differently than currently available TNF inhibitors by neutralizing soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors.
Lead Product(s): Pegipanermin
Therapeutic Area: Neurology Product Name: XPro1595
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
Xpro1595 (pegipanermin) is a next-generation inhibitor of tumor necrosis factor (TNF) that is currently in clinical trials in patients with neurologic disease by decreasing neuroinflammation and restoring innate immune cell function.
Lead Product(s): Pegipanermin
Therapeutic Area: Neurology Product Name: XPro1595
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2023
Details:
Xpro1595 (pegipanermin) is a next-generation inhibitor of tumor necrosis factor (TNF) that is currently in clinical trials in patients with neurologic disease by decreasing neuroinflammation and restoring innate immune cell function.
Lead Product(s): Pegipanermin
Therapeutic Area: Neurology Product Name: XPro1595
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2023
Details:
INKmune-generated tumor-primed NK (TpNK) cells can lyse a wide variety of NK-resistant tumors including leukemias, lymphomas, myeloma and solid tumors including prostate, renal cell, ovarian, nasopharyngeal, lung and breast cancer.
Lead Product(s): INKmune
Therapeutic Area: Oncology Product Name: INKmune
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2023
Details:
Xpro1595 (pegipanermin) is a next-generation inhibitor of tumor necrosis factor (TNF) that is currently in clinical trials in patients with neurologic disease by decreasing neuroinflammation and restoring innate immune cell function.
Lead Product(s): Pegipanermin
Therapeutic Area: Neurology Product Name: Xpro1595
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2023
Details:
INKmune-generated tumor-primed NK (TpNK) cells can lyse a wide variety of NK-resistant tumors including leukemias, lymphomas, myeloma and solid tumors including prostate, renal cell, ovarian, nasopharyngeal, lung and breast cancer.
Lead Product(s): INKmune
Therapeutic Area: Oncology Product Name: INKmune
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
